Xiaodong Liu
A5003379518- Renal cell carcinoma treatment
- Epigenetics and DNA Methylation
- Phagocytosis and Immune Regulation
- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
- Pancreatic and Hepatic Oncology Research
- Virus-based gene therapy research
- Renal and related cancers
- Immune Cell Function and Interaction
Westlake University
2025
Kunming Medical University
2024
First Affiliated Hospital of Kunming Medical University
2024
STEAP4 manifested differential expression and aberrant methylation in prostate cancer (PCa). Therefore, this study proposed to explore the effect of on PCa malignant phenotype vivo vitro possible molecular mechanisms using RNA-seq. The its prognostic diagnostic value was identified bioinformatics. After exogenous modulation STEAP4, cells examined functional assays nude mouse tumor models. STEAP4-related differentially expressed genes (DEGs) hub were characterized RNA-seq conjunction with...
Abstract Purpose: Fumarate hydratase–deficient renal cell carcinoma (FH-deficient RCC) is a rare and lethal subtype of kidney cancer. However, the optimal treatments molecular correlates benefits for FH-deficient RCC are currently lacking. Experimental Design: A total 91 patients with from 15 medical centers between 2009 2022 were enrolled in this study. Genomic bulk RNA-sequencing (RNA-seq) performed on 88 45 untreated RCCs, respectively. Single-cell RNA-seq was to identify biomarkers...
<div>AbstractPurpose:<p>Fumarate hydratase–deficient renal cell carcinoma (FH-deficient RCC) is a rare and lethal subtype of kidney cancer. However, the optimal treatments molecular correlates benefits for FH-deficient RCC are currently lacking.</p>Experimental Design:<p>A total 91 patients with from 15 medical centers between 2009 2022 were enrolled in this study. Genomic bulk RNA-sequencing (RNA-seq) performed on 88 45 untreated RCCs, respectively. Single-cell...
<p>Supplementary Figure 2. Treatment details and survival outcomes of patients with metastatic FH-deficient RCC. (A) Swimmer plot showing the treatment response duration each patient receiving first-line systemic treatments; (B) Progression-free for (C) Overall (OS) treatments.</p>
<p>Supplementary Figure 6. Validation of the FH-deficient RCC immune signature. (A) UMAP plot showing expression selected genes; (B) Correlations between six genes in signature and treatment response, significance differential (q value) was determined by two-sided Wilcoxon rank-sum test with Bonferroni FDR correction; (C) several related hallmark pathways, correction. *, q<0.05; **, q<0.01; ***, q<0.001; ****, q<0.0001.</p>
<p>Supplementary Figure 3. Forest plot showing the prognostic value of clinicopathologic and molecular features in patients treated with first-line ICI+TKI combination therapy. HR<1 indicates better survival comparator group, while HR>1 control group. TMB, tumor mutation burden; MUT, mutation; WT, wild type; TPS, proportion score; CCP, cell cycle progression; Sig., signature.</p>
<p>Supplementary Figure 6. Validation of the FH-deficient RCC immune signature. (A) UMAP plot showing expression selected genes; (B) Correlations between six genes in signature and treatment response, significance differential (q value) was determined by two-sided Wilcoxon rank-sum test with Bonferroni FDR correction; (C) several related hallmark pathways, correction. *, q<0.05; **, q<0.01; ***, q<0.001; ****, q<0.0001.</p>
<p>Supplementary Figure 5. Cell clusters and their distribution in a validation cohort by Dong et al.. (A) UMAP plot showing the sample of T cells; (B) all cells collected from four samples; (C) Dot marker gene expression for clusters; (D) Bar plots tissue (E) Tissue prevalence cell estimated Ro/e score.</p>
<p>Supplementary Figure 2. Treatment details and survival outcomes of patients with metastatic FH-deficient RCC. (A) Swimmer plot showing the treatment response duration each patient receiving first-line systemic treatments; (B) Progression-free for (C) Overall (OS) treatments.</p>
<p>Supplementary Figure 1. Survival outcomes of patients with synchronous and metachronous metastatic disease treatment flows. Overall survival (OS) for FH-deficient RCC in the overall systemic setting (A), ICI+TKI (B), TKI monotherapy (C); (D) Sankey diagram showing flows RCC.</p>
<p>Supplementary Figure 5. Cell clusters and their distribution in a validation cohort by Dong et al.. (A) UMAP plot showing the sample of T cells; (B) all cells collected from four samples; (C) Dot marker gene expression for clusters; (D) Bar plots tissue (E) Tissue prevalence cell estimated Ro/e score.</p>
<p>Supplementary Figure 1. Survival outcomes of patients with synchronous and metachronous metastatic disease treatment flows. Overall survival (OS) for FH-deficient RCC in the overall systemic setting (A), ICI+TKI (B), TKI monotherapy (C); (D) Sankey diagram showing flows RCC.</p>